Article Listing - Generics
Generic medicines pricing reforms deliver significant savings to Australian government, says CSES report
22 May 2013
Australia's 2010 Pharmaceutical Benefits Scheme (PBS) reforms have delivered the government significant savings. A report by Centre for Strategic Economic Studies, released this week, estimates that savings to government and general patients (non-health-card holding patients) will be up to A$18 billion ($17.53 billion) over eight years.
Novo A/S acquires Norway's Xellia Pharmaceuticals in $700 million deal
21 May 2013
Denmark-based Novo A/S, the holding company of the Novo Group and the major shareholder in Novo Nordisk and Novozymes, has purchased all shares of the Norwegian firm Xellia Pharmaceutical for around $700 million from 3i and other current shareholders. As a consequence of the transaction, Xellia will revert to Danish ownership with headquarters in Copenhagen.
Actavis confirms plan to acquire Warner Chilcott, in $8.5 billion deal
20 May 2013
US generics major Actavis (NYSE: ACT) revealed today (May 20) that it has entered into a definitive agreement to acquire Ireland-based specialty drugmaker Warner Chilcott (Nasdaq: WCRX) in a stock-for-stock transaction valued at around $8.5 billion (including $3 billion of debt). Actavis' shares gained 2.6% to $128.70 in premarket trading, while those of Warner Chilcott rose 3.3% to $19.85.
Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
20 May 2013
One of the most important preconditions for Turkey to reach a reformist, sustainable economic growth with high-added-value and to attract more direct foreign investment is to create an effective patent system at international standards, protecting intellectual property rights, comments the research-based Turkish pharma industry group, the AIFD.
Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
20 May 2013
India's National Pharmaceutical Pricing Authority (NPPA) last week announced plans that will bring down the prices of essential medicines, increase the number of drugs under price control, and alter the way the government regulates prices in the 720 billion-rupee ($13.17 billion) domestic market.
Impax launches authorized generic of Zomig, as Mylan debuts copy of Tricor in USA
20 May 2013
US drugmaker Impax Laboratories (Nasdaq: IPXL) says that its generics division, Global Pharmaceuticals, commenced shipment of an authorized generic version of Zomig (zolmitriptan) tablets and orally disintegrating tablets, 2.5mg and 5mg, in the USA, as part of a distribution, license, development and supply agreement with Anglo-Swedish drug major AstraZeneca (LSE: AZN).
US Senate confirms appointment of Marilyn Tavenner as CMS Administrator
16 May 2013
US Health and Human Services (HHS) Secretary Kathleen Sebelius announced that the US Senate has confirmed Marilyn Tavenner as Administrator of the Centers for Medicare & Medicaid Services (CMS).
Australia's 2013-14 Budget includes investment in health services and PBS
14 May 2013
The Australian government today (May 14) presented its Budget for 2013-2014, saying that it delivers A$43 billion ($43 billion) in savings to return the budget to surplus and fund key nation-building reforms.
Dr Reddy's 2012 revenues grew 20%, with earnings up 24%
14 May 2013
Dr Reddy's Laboratories (NYSE: RDY), India's second largest drugmaker, has announced its audited consolidated financial results for the fourth quarter and full year ended March 31, 2013, showing that consolidated revenues for the year were 116.3 billion rupees ($2.13 billion), recording year-on-year growth of 20%. Excluding the beneficial impact of olanzapine (Eli Lilly's antipsychotic drug Zyprexa) exclusivity in fiscal 2012, sales registered year-on-year growth of 26%.
Countries must fix critical access to medicines flaws in Trans-Pacific Trade Pact, says MSF
14 May 2013
As negotiations for the Trans-Pacific Partnership (TPP) restart in Lima, Peru, tomorrow (May 15), countries must prioritize fixing critical flaws in the agreement that could leave millions of people in developing countries with limited access to affordable generic medicines, international medical humanitarian organization Medecins Sans Frontieres (MSF) said today.
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
